Halozyme initiates Phase Ib/II oncology combination trial
US-based biotechnology firm Halozyme Therapeutics has initiated a Phase Ib/II clinical trial of PEGPH20 and atezolizumab (Tecentriq) combination to treat metastatic pancreatic ductal adenocarcinoma.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Adenocarcinoma | Biotechnology | Cancer & Oncology | Clinical Trials | Pancreas | Pharmaceuticals